Are compounded semaglutide and tirzepatide safe?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2027
Short answer
No, and since the shortages ended most compounding of semaglutide and tirzepatide is no longer permitted. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, ending enforcement discretion in 2025. FDA has documented dosing errors of 5 to 20 times the intended dose and hundreds of adverse event reports.
Get urgent care if: you think you have injected more than your intended dose, or you develop any of the following after a compounded or unlabelled GLP-1 product:
- Repeated vomiting, or inability to keep fluids down
- Severe upper abdominal pain radiating to the back
- Fainting, confusion, or very little urine output
- Sweating, shaking or loss of consciousness suggesting low blood sugar
- Fever, redness or swelling at an injection site
This answer will not be popular with anyone selling these products, so let me be direct. Compounded semaglutide and tirzepatide are not FDA approved, were only ever tolerated because of a shortage, and that shortage is over. The FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage resolved on 21 February 2025. Enforcement discretion for 503A pharmacies ended on 18 February 2025 for tirzepatide and 22 April 2025 for semaglutide, and for 503B outsourcing facilities on 19 March 2025 and 22 May 2025.
What the FDA has actually documented
In July 2024 the FDA alerted clinicians and patients to dosing errors with compounded injectable semaglutide. Patients had administered 5 to 20 times the intended dose. In one case a prescriber wrote 25 units instead of 5 units, causing severe vomiting. In another, 20 units were prescribed instead of 2, affecting three patients. Reported consequences included dehydration, fainting, acute pancreatitis and gallstones, with some patients requiring hospital admission. As of late 2024 the FDA had received more than 392 adverse event reports for compounded semaglutide and more than 215 for compounded tirzepatide.
The salt form problem
Many compounded products have used semaglutide sodium or semaglutide acetate. The FDA is unambiguous: "The salt forms are different active ingredients than is used in the approved drugs, which contain the base form of semaglutide." That is not a technicality. It means the substance in the vial is not the molecule tested in STEP 1 or SURMOUNT-1, and no human efficacy or safety data exist for it. The FDA has also warned about peptides sold online labelled for research use only with human dosing instructions, and about counterfeit products that may contain the wrong ingredient, no active ingredient, or harmful ingredients.
Where the rules stand in 2026
On 30 April 2026 the FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, which would permanently close large-scale compounding of these drugs. Narrow exceptions remain at 503A pharmacies where a patient's medical need genuinely cannot be met by the approved product, such as a documented excipient allergy. Wanting a different dose, a cheaper product or a sublingual formulation is not such a need. The World Health Organization noted in its December 2025 guideline that global demand has fuelled the spread of falsified and substandard GLP-1 products.
If you are currently using a compounded product, do not stop abruptly without a conversation, but do ask three questions: what exactly is the active ingredient and is it the base form, what facility made it and under what registration, and what is the concentration in milligrams per millilitre rather than in units. If those answers are not immediately available in writing, that is your answer.
The clinical detail
Regulatory timeline: tirzepatide shortage resolved 19 December 2024, with section 503A enforcement discretion ending 18 February 2025 and 503B ending 19 March 2025; semaglutide shortage resolved 21 February 2025, with 503A ending 22 April 2025 and 503B ending 22 May 2025. FDA proposed rule of 30 April 2026 would exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. FDA position: "Compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness." Documented dosing errors involved 5 to 20 fold overdoses, frequently arising from prescriptions written in insulin syringe units rather than milligrams. Adverse events reported include acute pancreatitis, cholelithiasis, dehydration and syncope.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2027
Sources
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. U.S. Food and Drug Administration
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration
- FDA moves to permanently close the door on compounded GLP-1s. Pharmacy Times
- WHO issues global guideline on the use of GLP-1 medicines in treating obesity, 1 December 2025. World Health Organization
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.